Zepbound Results: What the Trials Actually Show, Dose by Dose

Zepbound carries two FDA approvals, not one, and that sets this page apart from a general look at tirzepatide. The drug is identical to Mounjaro's, but the brand has its own trials and its own sleep apnea approval. It also answers a question many women ask before the first shot: does the low starting dose do anything?

How much weight does Zepbound help you lose, on average?

SURMOUNT-1 is the benchmark. Over 72 weeks, adults without diabetes lost about 15% of their starting weight on the 5 mg dose. On 10 mg, they lost about 19.5%. On the top 15 mg dose, they lost about 21%. On placebo, a dummy shot, they lost about 3%.

Those numbers count everyone assigned to a dose, including people who stopped early. So they're closer to a floor than a best case.

An average also hides a wide spread. About 85% to 91% of people on Zepbound lost at least 5% of their weight, the usual mark for a weight drug working. On placebo, about 35% did. At the high end, about half of people on 10 or 15 mg lost 20% or more, against about 3% on placebo. Landing below the average doesn't mean the drug failed you.

Does the 2.5 mg starting dose cause weight loss, or is it just for adjustment?

Mostly adjustment, and the trial design says so. Everyone on Zepbound in SURMOUNT-1 started at 2.5 mg for four weeks, then stepped up. It was never tested as its own treatment arm. So there's no honest trial figure for weight loss on 2.5 mg alone. If someone quotes one, it isn't from this trial.

What the low dose does is give your gut time to adjust before the level climbs. That's why nausea and other stomach side effects tend to be worst in the first weeks, then ease. Appetite is usually the first thing to shift. Food noise quiets, or a normal portion starts to feel like enough, often before the scale moves. A quiet scale in month one is the schedule working as designed.

What is Zepbound approved for besides weight loss?

This is where the brand stops being interchangeable with Mounjaro. On December 20, 2024, the FDA approved Zepbound for moderate to severe obstructive sleep apnea in adults with obesity. It was the first medicine approved for that condition. The approval sits on Zepbound's label, not Mounjaro's.

It rested on two SURMOUNT-OSA trials. Sleep apnea is measured by the apnea-hypopnea index, or AHI: how many times an hour breathing stops or becomes shallow. In one trial, Zepbound cut AHI by about 25 events an hour, against about 5 on placebo. In the other, it cut about 29, against about 6.

Far more people on Zepbound reached remission or mild sleep apnea without daytime sleepiness. That was about 42% against 16% on placebo in the first trial. In the second, it was about 50% against 14%.

Don't stretch the label further than it goes. Zepbound has no approval for lowering the risk of heart attack, stroke or heart-related death. Mounjaro gained that approval in August 2026, from a trial called SURPASS-CVOT, but only for adults with type 2 diabetes at high risk. A separate trial, SURMOUNT-MMO, is testing tirzepatide's heart effects in people with obesity who don't have diabetes. It has no results yet. For how Zepbound acts in the body, see what Zepbound is and how it works.

What does a realistic month-by-month timeline look like?

The steps below assume the dose climbs about every four weeks. If your prescriber holds you on a step longer, every later checkpoint moves out too.

• Month 1, on 2.5 mg: appetite usually shifts while the scale barely moves. This step is for comfort, not results.
• Month 3: the dose has climbed past the starting steps, and the scale usually starts to move more clearly.
• Month 6: many people are still climbing, since reaching 15 mg takes at least five months. Research on plateaus puts the typical leveling-off around six to nine months, depending on starting weight.
• Months 12 to 18: this is where SURMOUNT-1 measured its headline numbers, about 15% on 5 mg, 19.5% on 10 mg and 21% on 15 mg.
• After 18 months: loss tends to hold rather than keep climbing. That's a plateau settling in, not the drug losing its grip.

What do real before-and-after numbers show?

Strip away the marketing and 'before and after' really means a range of responses, each backed by real trial participants. In SURMOUNT-1, about one in ten people on Zepbound lost less than 5% of their weight. Most lost 10% or more. About half of those on the higher doses lost 20% or more.

None of these results is a verdict on effort. Response tracks the dose you reach, how steadily you take the weekly shot, and biology that doesn't show up on an intake form. A photo online can't show you any of that. A number tied to a specific week and dose can.

Is Zepbound's tirzepatide different from Mounjaro's?

Not in the body. The drug and the maker are the same, and the appetite timeline matches. Mounjaro results covers it week by week.

The labels differ, though. Since August 2026, Mounjaro's label raises the dose only if blood sugar needs it, while Zepbound's steps up on a schedule. Zepbound rests on SURMOUNT-1 for weight and SURMOUNT-OSA for sleep apnea. Mounjaro rests on the SURPASS trials for type 2 diabetes, and on SURPASS-CVOT for heart risk in that same group. The label also decides which insurance door opens. Zepbound alternatives, including Mounjaro compares price and access. Tirzepatide results covers the numbers behind both brands.

Do results look different at 40-plus, or in perimenopause?

This has been studied directly. A 2025 analysis of SURMOUNT-1, published in the journal Obesity, sorted women by reproductive stage. Premenopausal women lost about 26% of their weight on tirzepatide. Perimenopausal and postmenopausal women each lost about 23%. On placebo, all three groups lost 2% to 3%.

So being in perimenopause or past menopause trims the average a little, but the authors concluded the drug worked irrespective of reproductive stage. Falling estrogen likely explains the small gap. It moves fat toward the belly and works against insulin sensitivity.

Some small observational studies suggest women on hormone therapy may lose a bit more on these drugs. A 2026 clinical review notes they are small and retrospective, so they can't prove it. Hormone therapy is its own decision, for its own symptoms and risks. GLP-1 and menopause covers how the two fit together.

What actually determines your individual result?

Trial averages explain the shape of the curve. They don't predict your number. A few factors reliably move it:

• The dose you reach and tolerate: SURMOUNT-1 shows a gap of several points between 5 mg and 15 mg.
• How steadily you take it: a missed or late weekly dose interrupts the steady drug level these medicines depend on.
• Where you started: starting weight and metabolic health shape how much loss is realistic. That's biology, not a personal failing.
• Variation nobody has fully mapped yet: some of the gap between small and large responders likely comes down to genetics.

Is a weight plateau normal, or has Zepbound stopped working?

Normal, and the data puts a rough number on it. A 2025 analysis of SURMOUNT-1 and SURMOUNT-4 defined a plateau as less than 5% further change over 12 weeks. The typical time to reach one ran from about 24 weeks for people who started at a lower BMI to about 36 weeks at a higher one. BMI, or body mass index, is a ratio of weight to height. By week 72, roughly 88% to 90% of participants had reached a plateau.

A plateau isn't the drug quietly failing. It's your body settling at a new stable weight once the dose has been at its ceiling for a while. Weight steadily climbing back on an unchanged dose is different, and worth raising with your prescriber.

Does the weight, or the sleep apnea benefit, come back if you stop?

For weight, yes, at least partly. SURMOUNT-4 tested exactly this. Everyone took tirzepatide for 36 weeks first and lost about 21% on average. Then half kept taking it and half switched to placebo for a year.

The group that continued lost another 5.5% on average. The group switched to placebo regained 14% of their body weight. Most still ended well below where they started, because the regain came off a much larger loss.

For sleep apnea, nobody has measured what happens after stopping. SURMOUNT-OSA tracked people only while they stayed on Zepbound. Sleep apnea is closely tied to weight, and weight tends to return after stopping. So some of the breathing benefit would likely fade too. That's an educated guess, not a trial result.

What does Zepbound cost, and where do you start?

Cost depends on the form you get, your dose and your insurance. Zepbound comes as a single-dose pen, a multi-dose KwikPen and a vial, and each savings route covers a different form:

• Lilly's savings card, with commercial insurance that covers Zepbound: as little as $25 a month for the single-dose pen.
• LillyDirect self-pay, vial or KwikPen: about $299 a month at 2.5 mg and $399 at 5 mg. From 7.5 mg up, it's $449 if you refill within 45 days, otherwise about $499 at 7.5 mg and $699 from 10 mg.
• Medicare's GLP-1 Bridge: $50 a month for the KwikPen, for people who meet its eligibility rules.